Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 3 - Drugs for disorders of the metabolism
Patents for A61P 3 - Drugs for disorders of the metabolism (129,789)
10/2003
10/29/2003EP1355890A1 1, 2, 4-oxadiazole derivatives as hppar alpha agonists
10/29/2003EP1355888A1 Quinazolinone derivatives
10/29/2003EP1355884A1 Nicotinamide biaryl derivatives useful as inhibitors of pde4 isozymes
10/29/2003EP1355698A2 Insulin receptor activators for the treatment of metabolic disorders in humans resulting from treatment of hiv infection with hiv protease inhibitors
10/29/2003EP1355676A2 Protecting therapeutic compositions from host-mediated inactivation
10/29/2003EP1355657A2 Gssp3 polynucleotides and polypeptides and uses thereof
10/29/2003EP1355651A2 Treatment of diabetes mellitus using vardenafil
10/29/2003EP1355645A2 Method for treating fibrotic diseases or other indications iiic
10/29/2003EP1355644A2 The use of substituted azetidinone compounds for the treatment of sitosterolemia
10/29/2003EP1355643A2 Epoxyvibsanin b
10/29/2003EP1355639A2 Substituted carbostyril derivatives as 5-ht1a receptor subtype agonists
10/29/2003EP1355638A2 Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states
10/29/2003EP1355542A2 Nutritional composition with health promoting action containing oligosaccharides
10/29/2003EP1257527B1 (2s)-aminoindan derivatives, a process for their preparation and their use as selective dopamine d3 ligands
10/29/2003EP1235787B1 $g(b)2-ADRENERGIC RECEPTOR AGONISTS
10/29/2003EP1214302B1 Substituted 3-phenyl-5-alkoxi-1,3,4-oxdiazol-2-ones and their use as lipase inhibitors
10/29/2003EP1204429B1 Sustained release formulation of a peptide
10/29/2003EP1107940B1 Vitamin d3 mimics
10/29/2003EP1007093B1 Treatment of disorders using interleukin-9
10/29/2003EP0970095B1 Novel benzimidazole inhibitors of fructose-1,6-bisphosphatase
10/29/2003EP0941122B1 Compositions for polynucleotide delivery
10/29/2003EP0835129B1 Prevention of a disease having the characteristics of diabetes
10/29/2003CN1452622A Piperzine devivs.
10/29/2003CN1452613A Amorphous torasemide modification
10/29/2003CN1452610A Compound, compositions and methods for preventing neurodegeneration in acute and chronic injuries in central nervous system
10/29/2003CN1452497A Combinations of SSRI and estrogenic agents
10/29/2003CN1452490A Composition and method for intervening neuronal death using sulfasalazine
10/29/2003CN1452483A IL-8 receptor antagonists
10/29/2003CN1452482A Synergistic compositions contg. choline base and cuccinic acid for insulin resistance and diabetes
10/29/2003CN1452461A Compositions and methods for body weight management
10/29/2003CN1451427A Hypotensive and hypolipemic tea
10/29/2003CN1451397A Guava leaf tea and producing method thereof
10/29/2003CN1451392A Antihyperlipidemia active carbon capsule
10/29/2003CN1451390A Medicine use of cyclodextrin derivs. and medicine composition thereof
10/29/2003CN1451385A Oral compound hypoglycemic medicine
10/29/2003CN1125818C Amino acid derivatives of substituted quinexaline 2,3-dione derivatives as glutamate receptor antagonists
10/29/2003CN1125646C Solid beverage for prevention and control of essential hypertension and productive method thereof
10/29/2003CN1125641C Hongkong foot treating ointment
10/29/2003CN1125638C Stable slow release vitamin C preparation and its production process
10/29/2003CN1125637C Application of 5,3',5'-trihydroxy-7-methoxyl dihydroflavone in preparing medicine
10/29/2003CN1125601C Powdered prolycopene preparation, mfg. method thereof and use of same
10/29/2003CN1125595C Oral composition with cardiovascular health and senility delaying functions
10/29/2003CA2445913A1 Method of treatment
10/28/2003US6639113 Dispersing in an aqueous protecting colloids comprising at least one partially hydrolyzed soybean protein, drying by dehydration and desolventizing; use as additive to foods, pharmaceuticals and/or animal feeds
10/28/2003US6639078 Assays for ligands for nuclear receptors
10/28/2003US6638969 Combinations of ileal bile acid transport inhibitors and fibric acid derivatives for cardiovascular indications
10/28/2003US6638957 Inhibition of 1-deoxy-D-xylulose-5-phosphate metabolic pathway
10/28/2003US6638942 Spiro-indolines as Y5 receptor antagonists
10/28/2003US6638936 Treatment of obesity in mammals, comprising administering to mammal in need of such treatment, treatment of obsessive compulsive disorder in mammals, comprising administering to a mammal treatment of depression in mammals
10/28/2003US6638934 2,3,4,4a,5,6-hexahydro-1H-pyrazino(1,2-a)quinoxaline derivatives; treating depression, schizophrenia; (5-hydroxytryptamine=5HT) 5HT2a antagonist or a 5HT2c agonist
10/28/2003US6638927 Melanocortin-4 receptor (MC4-R) agonists; treating obesity or diabetes; 4-((N-cyclohexyl-3,5-dimethyl-piperazine-1-carboximidoyl)-amino)-N-(2-(2,4 -dichlorophenyl) -ethyl)-benzamide for example
10/28/2003US6638926 Pyrazole compounds useful as protein kinase inhibitors
10/28/2003US6638922 4-dedimethylaminotetracycline derivatives
10/28/2003US6638906 Amphiphilic polymers and polypeptide conjugates comprising same
10/28/2003US6638767 Methods for delivering compounds into a cell
10/28/2003US6638765 Platform for the differentiation of cells
10/28/2003US6638545 To treat cellulose; oral administration of trans-resveratrol lipase inhibitor; dietetics
10/28/2003US6638542 Synergistic mixture of procyanidin and citric acid
10/28/2003US6638540 Plant extracts for the treatment of increased bone resorption
10/28/2003US6638539 Trace elements
10/28/2003CA2252701C Halo-substituted protein kinase c inhibitors
10/28/2003CA2058020C Short peptides with insulin activity
10/23/2003WO2003087818A2 Diagnostic and therapeutic use of kremen 1 and 2, inhibitors of the canonical wnt-signaltransduction
10/23/2003WO2003087399A1 Nad)p)h oxidase inhibitors for increased glucose uptake and treatment of type ii diabetes
10/23/2003WO2003087383A1 Compositions for delivering enyzmes involved in amino acid metabolism using recombinant ademo-associated virus virons (raav virons), and method and use for treating aminoi acid metabolic disorders using such raav virons
10/23/2003WO2003087349A1 METHOD OF FORMING PANCREATIC β CELLS FROM MESENCHYMAL CELLS
10/23/2003WO2003087344A1 New strains capable of producing conjugated linoleic acid, capsulated composition comprising them, and the preparation methods thereof
10/23/2003WO2003087333A2 Modulation of stem and progenitor cell differentiation, assays, and uses thereof
10/23/2003WO2003087174A2 Carbocyclic and oxacarbocyclic fumaric acid oligomers
10/23/2003WO2003087139A2 Treatment of gastroparesis
10/23/2003WO2003087134A2 G-protein coupled receptor ligands and methods
10/23/2003WO2003087108A2 Mimics of acyl coenzyme-a, compositions thereof, and methods of cholesterol management and related uses
10/23/2003WO2003087093A1 Novel glucopyranoside, process for isolation thereof, pharmaceutical composition containing same and use thereof
10/23/2003WO2003087088A2 (condensed) pyrimidone and (condensed) pyridone compounds, processes for their preparation, and pharmaceutical compositions containing them
10/23/2003WO2003087086A2 Substituted indoles
10/23/2003WO2003087080A1 Medicinal composition for improving angiotension-regulating function of blood vessel endothelium
10/23/2003WO2003087046A1 Novel aminotetraline compounds for use in mch receptor related disorders
10/23/2003WO2003087045A1 Novel methoxybenzamide compounds for use in mch receptor related disorders
10/23/2003WO2003087044A2 Novel carboxamide compounds for use in mch receptor related disorders
10/23/2003WO2003087040A2 Mimics of acyl coenzyme-a comprising pantolactone and pantothenic acid derivatives, compositions thereof, and methods of cholesterol management and related uses
10/23/2003WO2003087038A1 Crystal forms of n-(trans-4-isopropylcyclohexylcarbonyl)-d-phenylalanine
10/23/2003WO2003087037A1 Substituted aryl amides
10/23/2003WO2003086563A2 Diabetes imaging probes
10/23/2003WO2003086516A1 Therapeutic dry powder preparation
10/23/2003WO2003086468A1 Aqueous dispersible steryl ester compositions
10/23/2003WO2003086458A1 Recombinant anti-interleukin-9 antibodies
10/23/2003WO2003086444A1 Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
10/23/2003WO2003086436A1 Enteric fat absorption inhibitors contaiing plant extract and foods containing the same
10/23/2003WO2003086417A1 Use of pyrimidine nucleotides for the treatment of affections of the peripheral nervous system
10/23/2003WO2003086415A1 Method for inhibiting bone resorption with an alendronate and vitamin d formulation
10/23/2003WO2003086410A1 Pharmaceutical compositions comprising a 11-beta hydroxysteroid dehydrogenase inhibitor and a diuretic agent
10/23/2003WO2003086400A1 N-substituted pyridinone and pyrimidinone derivatives for use as lp-pla2 inhibitors in the treatment of artherosclerosis
10/23/2003WO2003086395A1 Tyrosine kinase inhibitors
10/23/2003WO2003086390A1 Imidazole compounds as anti-inflammatory and analgesic agents
10/23/2003WO2003086384A1 Stabilized ascorbic acid derivatives
10/23/2003WO2003086351A1 Compositions and methods for dosing liposomes of certain sizes to treat or prevent disease
10/23/2003WO2003086324A2 Preparation and use of a stable formulation of allosteric effector compounds
10/23/2003WO2003086317A2 Protein a compositions and methods of use
10/23/2003WO2003086315A2 Tyrosine kinase inhibitors
10/23/2003WO2003086314A2 Tyrosine kinase inhibitors
1 ... 861 862 863 864 865 866 867 868 869 870 871 872 873 874 875 876 877 878 879 880 881 ... 1298